Recent advances in pharmacokinetic modeling
Author:
- 13 February 2007
- journal article
- review article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 28 (3) , 135-143
Abstract
A major part of the science of pharmacokinetics is the modeling of the underlying processes that contribute to drug disposition. The purpose of pharmacokinetic models is to summarize the knowledge gained in preclinical and clinical studies at various stages in drug development and to rationally guide future studies with the use of adequately predictive models. This review highlights a variety of recent advances in mechanistic pharmacokinetic modeling. It is aimed at a broad audience, and hence, an attempt was made to maintain a balance between technical information and practical applications of pharmacokinetic modeling. It is hoped that drug researchers from all disciplines would be able to get a flavor of the function and capacity of pharmacokinetic modelers and their contribution to drug development. While this review is not intended to be a technical reference on modeling approaches, the roles of statistical applications and population methodologies are discussed where appropriate. Copyright © 2007 John Wiley & Sons, Ltd.Keywords
This publication has 43 references indexed in Scilit:
- Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin After Single and Multiple Doses in Healthy VolunteersThe Journal of Clinical Pharmacology, 2004
- Cyclosporine Microemulsion (Neoral®) Absorption Profiling and Sparse-sample Predictors During the First 3 Months after Renal TransplantationAmerican Journal of Transplantation, 2002
- Maximum A Posteriori Bayesian Estimation of Oral Cyclosporin Pharmacokinetics in Patients with Stable Renal TransplantsClinical Pharmacokinetics, 2002
- Application of a Gamma Model of Absorption to Oral CyclosporinClinical Pharmacokinetics, 2001
- Role of Population Pharmacokinetics in Drug DevelopmentClinical Pharmacokinetics, 1997
- DISCONTINUOUS ORAL ABSORPTION PHARMACOKINETIC MODEL AND BIOAVAILABILITY OF 1-(2-FLUORO-5-METHYL-β-L-ARABINOFURANOSYL)URACIL (L-FMAU) IN RATSBiopharmaceutics & Drug Disposition, 1996
- Population Pharmacokinetics/Dynamics*Annual Review of Pharmacology and Toxicology, 1992
- Use of a Pharmacokinetic Model Incorporating Discontinuous Gastrointestinal Absorption to Examine the Occurrence of Double Peaks in Oral Concentration–Time ProfilesPharmaceutical Research, 1992
- Pharmacokinetics1982
- Modelling of individual pharmacokinetics for computer-aided drug dosageComputers and Biomedical Research, 1972